Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...

The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even ...

The tax bill recently signed by President Trump represents the largest cut to federal healthcare spending ever, according to ...

Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to the drugs remains challenging. The medications still amount to around $500 ...

The U.S. Supreme Court declined to review an appeals court ruling that struck down key parts of an Oklahoma law regulating ...

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through ...

In a 2024 report, unusually approved by Democrats and Republicans, the U.S. House Committee on Oversight found “PBMs frequently tout the savings they provide for payers and patients through ...

Kentucky’s independent pharmacies, facing ongoing financial pressure, had hoped for relief from a new law meant to give them ...

The Prescription Drug Affordability Act will impose new restrictions on practices of pharmacy benefit managers, or PBMs, a ...

For far too long, these companies have used our nation’s drug supply chain to benefit shareholders and executives while ...